The BTD Knockout SK-HEP-1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal cell population featuring targeted disruption of the BTD gene within the human SK-HEP-1 hepatic adenocarcinoma cell line. This polyclonal knockout pool provides a genetically heterogeneous loss-of-function model for investigating biotinidase biology, avoiding the clonal selection biases associated with single-cell-derived knockout lines. It enables robust population-level studies of BTD-dependent metabolic processes and regulatory mechanisms.
The SK-HEP-1 host cell line was originally established from the ascitic fluid of a patient with liver adenocarcinoma. These cells display an epithelial morphology and retain many liver-specific metabolic functions, including the capacity for detoxification and synthesis of plasma proteins. As a widely utilized hepatocellular carcinoma model, SK-HEP-1 is advantageous for dissecting the intersection between cancer biology and hepatic metabolism. Its derivation from a metastatic site makes it particularly relevant for examining the molecular underpinnings of aggressive liver cancer phenotypes.
The BTD gene encodes biotinidase, an enzyme responsible for hydrolyzing biocytin (biotinyl-??-lysine) to recover free biotin. This recycled biotin serves as an essential cofactor for four biotin-dependent carboxylases: acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, and ??-methylcrotonyl-CoA carboxylase. These enzymes catalyze critical steps in fatty acid synthesis, gluconeogenesis, and branched-chain amino acid catabolism. Biotinidase activity is also required for histone biotinylation, an epigenetic modification that influences chromatin structure and gene expression. The enzyme is regulated upstream by hepatocyte nuclear factors and by biotin availability, and it interacts directly with biotin and biocytin. Holocarboxylase synthetase and the sodium-dependent multivitamin transporter (SMVT) are additional key components of this biotin recycling network. CRISPR/Cas9-mediated disruption of BTD therefore abrogates biotin recycling, leading to impaired holocarboxylase formation, reduced carboxylase activities, and altered histone biotinylation patterns.
In the context of SK-HEP-1 hepatocellular carcinoma cells, BTD knockout is expected to compromise metabolic flexibility and detoxification capacity owing to deficient biotin-dependent carboxylase function. This model can recapitulate aspects of biotinidase deficiency at the cellular level and provides a platform to explore how biotin recycling influences cancer cell proliferation, survival, and metabolic reprogramming. Given the host line??s hepatic origin, the knockout cells are especially suited for investigating the role of biotin metabolism in liver cancer progression, drug metabolism, and the cellular response to biotin deprivation or supplementation.
Researchers can employ these polyclonal knockout cells in a broad spectrum of assays, including immunoblotting for BTD protein, enzymatic biotinidase activity measurements, LC-MS?Cbased biotin quantitation, and Seahorse metabolic flux analysis for real-time assessment of glycolytic and oxidative metabolism. Chromatin immunoprecipitation sequencing (ChIP-seq) can be used to map histone biotinylation changes, while cell viability assays under biotin-restricted conditions reveal functional dependencies. Transcriptional profiling via RT-qPCR of biotin-responsive genes further elucidates downstream effects. For additional technical details, protocols, or ordering assistance, please contact Ascent Research.
